RECORD Confirms Heart Failure Risk With Rosiglitazone: Final results show no increase in MI risk.

NEW ORLEANS — Findings from the RECORD study confirm the growing consensus that rosiglitazone should not be used in patients with a history of heart failure, with previous problems that might have led to myocardial damage, or in women who are at increased risk for fractures.